Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rieke Alten

Showing results (1-10 of 157) with videos related to

Pageof 16
Sort By:
Therapeutic Advances in Musculoskeletal Disease|August 8, 2012
Tocilizumab: a novel humanized anti-interleukin 6 receptor antibody for the treatment of patients with rheumatoid arthritisRieke Alten
Expert Review of Clinical Immunology|February 1, 2012
Chronotherapy with modified-release prednisone in patients with rheumatoid arthritisRieke Alten
Zeitschrift Fur Rheumatologie|June 20, 2022
[This is how we treat rheumatoid nodules in patients with rheumatoid arthritis in remission]Max Mischkewitz, Rieke Alten
Joint Bone Spine|December 12, 2018
New concepts to reduce glucocorticoid toxicityRieke Alten, Max Mischkewitz
Neuroimmunomodulation|September 18, 2014
Hypothalamic-pituitary-adrenal axis function in patients with rheumatoid arthritis treated with different glucocorticoid approachesRieke Alten, Edgar Wiebe
Nature Reviews. Rheumatology|July 17, 2021
2021 ACR guideline reflects changes in RA treatmentRieke Alten, Max Mischkewitz
Annals of Medicine|May 9, 2013
Tocilizumab: a novel humanized anti-interleukin 6 (IL-6) receptor antibody for the treatment of patients with non-RA systemic, inflammatory rheumatic diseasesRieke Alten, Tazio Maleitzke
Nature Reviews. Rheumatology|October 31, 2023
Maximizing the success of biosimilar implementationRieke Alten, Max Weinbrecht-Mischkewitz
Seminars in Arthritis and Rheumatism|June 11, 2015
Clinical trial development for biosimilarsRieke Alten, Bruce N Cronstein
International Journal of Rheumatic Diseases|January 30, 2014
Dose optimization of infliximab in patients with rheumatoid arthritisRieke Alten, Filip van den Bosch
Pageof 16

Showing results (1-10 of 157) with videos related to

Sort By:
Pageof 16
Therapeutic Advances in Musculoskeletal Disease|August 8, 2012
Tocilizumab: a novel humanized anti-interleukin 6 receptor antibody for the treatment of patients with rheumatoid arthritisRieke Alten
Expert Review of Clinical Immunology|February 1, 2012
Chronotherapy with modified-release prednisone in patients with rheumatoid arthritisRieke Alten
Zeitschrift Fur Rheumatologie|June 20, 2022
[This is how we treat rheumatoid nodules in patients with rheumatoid arthritis in remission]Max Mischkewitz, Rieke Alten
Joint Bone Spine|December 12, 2018
New concepts to reduce glucocorticoid toxicityRieke Alten, Max Mischkewitz
Neuroimmunomodulation|September 18, 2014
Hypothalamic-pituitary-adrenal axis function in patients with rheumatoid arthritis treated with different glucocorticoid approachesRieke Alten, Edgar Wiebe
Nature Reviews. Rheumatology|July 17, 2021
2021 ACR guideline reflects changes in RA treatmentRieke Alten, Max Mischkewitz
Annals of Medicine|May 9, 2013
Tocilizumab: a novel humanized anti-interleukin 6 (IL-6) receptor antibody for the treatment of patients with non-RA systemic, inflammatory rheumatic diseasesRieke Alten, Tazio Maleitzke
Nature Reviews. Rheumatology|October 31, 2023
Maximizing the success of biosimilar implementationRieke Alten, Max Weinbrecht-Mischkewitz
Seminars in Arthritis and Rheumatism|June 11, 2015
Clinical trial development for biosimilarsRieke Alten, Bruce N Cronstein
International Journal of Rheumatic Diseases|January 30, 2014
Dose optimization of infliximab in patients with rheumatoid arthritisRieke Alten, Filip van den Bosch
Pageof 16